is tirzepatide a controlled substance for diabetes: on track to SURPASS current therapy Shifting the Scales: Tirzepatide's Breakthrough

Additionally, in patients with T2DM, a 12-month GLP-1RA treatment was associated with increased endothelial glycocalyx thickness and reduced arterial stiffness, which could contribute to blood pressure reduction and stroke prevention [26]

Gallbladder issues, including acute cholecystitis and choledocholithiasis, may cause right upper abdominal pain, nausea, and jaundice

Hypoglycemia can cause symptoms like sweating, shaking, confusion, weakness, and dizziness

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously a mechanism that sets it apart from existing licensed treatments